Leu Martin, Patzer Christoph, Guhlich Manuel, Possiel Jacqueline, Pilavakis Yiannis, Schirmer Markus Anton, Rieken Stefan, Dröge Leif Hendrik
Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany.
Department of Otorhinolaryngology, University Medical Center Göttingen, 37075 Göttingen, Germany.
Cancers (Basel). 2021 Jul 6;13(14):3384. doi: 10.3390/cancers13143384.
Locally advanced head and neck squamous cell carcinomas (HNSCC) are often managed with surgery followed by postoperative radiochemotherapy (RCT). With the general increase in life expectancy, the proportion of elderly patients with HNSCC is expected to grow rapidly. Until now, a deeper understanding of specific management strategies for these patients in clinical routine was lacking. In the present study, we compared elderly patients (≥70 years, = 52) and younger patients ( = 245) treated with postoperative RCT for HNSCC at our tertiary cancer center. All patients were irradiated with modern radiotherapy techniques (IMRT/VMAT). Patients ≥70 years of age had more comorbidities. Additionally, elderly patients less frequently received concomitant systemic treatment. The rates of mucositis and dermatitis were lower in patients ≥70 years. Elderly patients had significantly worse overall and progression-free survival. Locoregional and distant control were comparable in elderly and younger patients. In conclusion, postoperative RCT is a safe and effective treatment option in patients ≥70 years. In light of comorbidities and poor overall survival rates, benefits and harms of radiotherapy and concomitant systemic treatment should be weighed carefully. When exclusively applying up-to-date radiotherapy techniques with, at the same time, careful use of concomitant systemic therapy, favorable acute toxicity profiles are achieved.
局部晚期头颈部鳞状细胞癌(HNSCC)通常采用手术治疗,术后进行放化疗(RCT)。随着预期寿命的普遍提高,老年HNSCC患者的比例预计将迅速增长。到目前为止,临床常规中对这些患者的具体管理策略缺乏更深入的了解。在本研究中,我们比较了在我们的三级癌症中心接受HNSCC术后RCT治疗的老年患者(≥70岁,n = 52)和年轻患者(n = 245)。所有患者均采用现代放疗技术(IMRT/VMAT)进行照射。≥70岁的患者合并症更多。此外,老年患者接受同步全身治疗的频率较低。≥70岁患者的黏膜炎和皮炎发生率较低。老年患者的总生存期和无进展生存期明显较差。老年患者和年轻患者的局部区域控制和远处控制相当。总之,术后RCT是≥70岁患者的一种安全有效的治疗选择。鉴于合并症和总体生存率较低,应仔细权衡放疗和同步全身治疗的利弊。当专门应用最新的放疗技术,同时谨慎使用同步全身治疗时,可获得良好的急性毒性反应。